- **Pelthos Therapeutics Inc. (PTHS)** commercially launched Zelsuvmi in **July 2025** as the first and only at-home treatment for Molluscum contagiosum (MC).  **[1919246_0001753926-25-001606_g084975_ex99-1.htm:2]** **[1919246_0001753926-25-001606_g084975_ex99-1.htm:7]** 
- Zelsuvmi targets a significant market, with up to **6 million new annual cases** in the U.S. and a total addressable market potential exceeding **$20 billion**.  **[1919246_0001753926-25-001606_g084975_ex99-1.htm:2]** **[1919246_0001753926-25-001606_g084975_ex99-1.htm:7]** 
- The company forecasts **peak net revenues of $175 million per annum by 2028** for Zelsuvmi.  **[1919246_0001753926-25-001606_g084975_ex99-1.htm:2]** 
- During its early launch phase in Q3 2025, Zelsuvmi recorded **2,716 TRx Units** and attracted **1,169 unique prescribers**.  **[1919246_0001753926-25-001606_g084975_ex99-1.htm:5]** 
- Clinical trials demonstrated strong efficacy, with a mean lesion count reduction of **58%** and complete clearance in **32.4%** of patients at week 12.  **[1919246_0001753926-25-001606_g084975_ex99-1.htm:4]** **[1919246_0001753926-25-001606_g084975_ex99-1.htm:7]**

Pelthos Therapeutics Inc. Provides Update on Zelsuvmi Commercial Launch

- Pelthos Therapeutics Inc. **commercially launched ZELSUVMI™** (berdazimer) topical gel, 10.3%, in **July 2025**.  **[1919246_0001753926-25-001425_g084940_ex99-1.htm:2]** **[1919246_0001753926-25-001425_g084940_ex99-1.htm:6]**  ZELSUVMI™ is the **first and only FDA-approved at-home treatment** for _molluscum contagiosum_, having received FDA approval in **January 2024**.  **[1919246_0001753926-25-001425_g084940_ex99-2.htm:0]** **[1919246_0001753926-25-001425_g084940_ex99-1.htm:6]** 
- The company forecasts **peak net revenue of $175 million per annum by 2028** for ZELSUVMI™, targeting a total addressable market for _molluscum contagiosum_ in excess of **$20 billion** with up to **6 million annual cases** in the U.S..  **[1919246_0001753926-25-001425_g084940_ex99-1.htm:2]** **[1919246_0001753926-25-001425_g084940_ex99-1.htm:6]**  
- In its early launch phase, ZELSUVMI™ recorded **892 TRx Units** and **501 unique prescribers** by **August 22, 2025**.   
- CEO Scott Plesha and CFO Frank Knuettel are scheduled to present at the **2025 Wells Fargo Healthcare Conference** on **September 3, 2025**, to provide updates on the product pipeline and the commercial launch of ZELSUVMI™.  **[1919246_0001753926-25-001425_g084940_ex99-2.htm:0]** **[1919246_0001753926-25-001425_g084940_8-k.htm:1]**

Pelthos Therapeutics (PTHS)